Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials

Video content above is prompted by the following:

• Based on the data seen in the EMBER-3 trial, how do you anticipate incorporating imlunestrant plus abemaciclib into your treatment sequencing for patients with HR+/HER2– metastatic BC? In which patients and in which line of therapy would you consider using this combination?
  • Based on subgroup data, how might you consider these factors in your clinical decision-making?
    • ESR1 mutation vs wild type
    • Prior CDK4/6i
    • Duration of prior CDK4/6i
    • Presence of visceral metastases
• Please highlight other trials of note investigating SERDs in HR+/HER2– BC:
  • SERENA-2: camizestrant vs fulvestrant
  • OPERA-01: palazestrant vs standard-of-care endocrine therapy
  • Any others (eg, EMBER-4, SERENA-4,ELEVATE, etc)